Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02266329 · ClinicalTrials.gov registry record · Phase 1
Chronic Postconcussive Headache: A Placebo-Controlled Treatment Trial of Prazosin
A Phase 1 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 89
- Enrollment target
NCT02266329: Completed Phase 1 study, sponsored by VA Office of Research and Development.
NCT02266329 is a Phase 1 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 89 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02266329, a Phase 1 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 89 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if prazosin is more effective than placebo in decreasing frequency, severity, disability, and other negative effects of headaches related to mild traumatic brain injury in Service Members and Veterans.
Interventions
- DRUG placebo
- DRUG prazosin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2016-01-04 |
| Est. Completion | 2023-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02266329
The ClinicalTrials.gov registry entry for NCT02266329 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02266329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02266329 about?
NCT02266329 is a clinical study titled "Chronic Postconcussive Headache: A Placebo-Controlled Treatment Trial of Prazosin". The purpose of this study is to determine if prazosin is more effective than placebo in decreasing frequency, severity, disability, and other negative effects of headaches related to mild traumatic brain injury in Service Members and Veterans.
What is the current status of trial NCT02266329?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 89 participants. The study started on 2016-01-04. Estimated completion is 2023-09-30.
What interventions are being tested in trial NCT02266329?
The interventions under investigation include: placebo (DRUG), prazosin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02266329?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.